Financial Performance - As of September 30, 2025, the company had an accumulated deficit of $192.8 million and expects to continue incurring net losses for the foreseeable future [115]. - For the nine months ended September 30, 2025, the company recognized $13.0 million in revenue, an increase from $7.0 million for the same period in 2024, primarily due to higher license revenue from the Maruho Japan Agreement [129]. - The company reported a net loss of $40.6 million for the nine months ended September 30, 2025, compared to a net loss of $46.1 million for the same period in 2024 [128]. - Total operating expenses for the nine months ended September 30, 2025, were $64.4 million, compared to $55.6 million for the same period in 2024 [128]. - Other income, net for the nine months ended September 30, 2025, was $10.8 million, up from $2.5 million in 2024, mainly due to a decrease in the fair value of convertible preferred stock forward [135]. - Net cash used in operating activities was $59.7 million for the nine months ended September 30, 2025, compared to $39.7 million in 2024, attributed to a net loss of $40.6 million [138][139]. - Cash provided by financing activities for the nine months ended September 30, 2025, was $63.9 million, primarily from the sale of Series C Preferred Stock [143]. Research and Development - Research and development expenses for the nine months ended September 30, 2025, were $53.6 million, up from $46.4 million in 2024, driven by increased clinical trial expenses for EVO756 [131]. - The company has two product candidates, EVO756 and EVO301, currently in Phase 2 trials, with plans for broad expansion across additional chronic inflammatory diseases [113]. - The company expects ongoing increases in research and development expenses, general and administrative expenses, and capital expenditures [145]. Funding and Financial Obligations - The company expects to require substantial additional funding to further develop its product candidates and support ongoing operations [117]. - Future funding requirements will depend on various factors, including the progress of clinical trials and the need for additional product candidates [147]. - The company may require additional financing to advance product candidates and fund operations, which could lead to dilution of existing stockholders' interests [146]. - Under the Dermira License Agreement, the company is obligated to pay up to $135.0 million in development milestones and up to $720.0 million in sales milestones for all licensed products [121]. - The company entered into a strategic collaboration with Maruho, granting an exclusive license to develop and commercialize EVO756 in Japan, with potential payments of up to $60.0 million [125]. - The company also entered into a license agreement with AprilBio for EVO301, with an upfront payment of $15.0 million and potential milestone payments up to $460.0 million [127]. Operational Expenses - General and administrative expenses increased to $3.7 million for the three months ended September 30, 2025, compared to $3.2 million in 2024, primarily due to higher personnel costs and stock-based compensation [134]. - The company executed a 63-month lease agreement for office space in Palo Alto, California, with annual payments of approximately $1.5 million for the first three years [149]. Cash Position - As of September 30, 2025, the company maintained $76.1 million in cash, cash equivalents, and short-term investments, and expects to fund operations into the second half of 2028 with net proceeds from its IPO [137]. Company Classification - The company remains classified as an emerging growth company, allowing it to delay the adoption of certain accounting standards [154].
Evommune(EVMN) - 2025 Q3 - Quarterly Report